XFOR X4 Pharmaceuticals Inc
Price (delayed)
$0.228
Market cap
$39.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.19
Enterprise value
$61.98M
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4
Highlights
X4 Pharmaceuticals's gross profit has soared by 180% from the previous quarter
The revenue has surged by 128% since the previous quarter
The EPS has dropped by 138% since the previous quarter but it has soared by 67% year-on-year
X4 Pharmaceuticals's net income has plunged by 123% from the previous quarter but it has soared by 63% YoY
The equity has plunged by 63% from the previous quarter and by 57% YoY
The quick ratio has declined by 37% year-on-year and by 32% since the previous quarter
Key stats
What are the main financial stats of XFOR
Market
Valuations
Earnings
Shares outstanding
173.66M
Market cap
$39.6M
Enterprise value
$61.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
17.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.24
Revenue
$2.56M
Gross profit
$1.76M
Operating income
-$36.4M
Net income
-$37.45M
EBIT
-$28.37M
EBITDA
-$25.99M
Free cash flow
-$138.23M
Per share
Balance sheet
Liquidity
EPS
-$0.19
EPS diluted
-$0.19
Free cash flow per share
-$0.69
Book value per share
$0.13
Revenue per share
$0.01
TBVPS
$0.59
Total assets
$146.45M
Total liabilities
$124.3M
Debt
$78.09M
Equity
$22.15M
Working capital
$79.3M
Debt to equity
3.53
Current ratio
3.41
Quick ratio
3.16
Net debt/EBITDA
-0.86
Margins
Efficiency
Dividend
EBITDA margin
-1,016.5%
Gross margin
68.8%
Net margin
-1,464.6%
Operating margin
-1,423.6%
Return on assets
-23.1%
Return on equity
-84.5%
Return on invested capital
-31.1%
Return on capital employed
-25%
Return on sales
-1,109.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XFOR stock price
How has the X4 Pharmaceuticals stock price performed over time
Intraday
2.84%
1 week
-15.37%
1 month
-42.29%
1 year
-83.48%
YTD
-68.92%
QTD
-3.55%
Financial performance
How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$2.56M
Gross profit
$1.76M
Operating income
-$36.4M
Net income
-$37.45M
Gross margin
68.8%
Net margin
-1,464.6%
X4 Pharmaceuticals's gross profit has soared by 180% from the previous quarter
The revenue has surged by 128% since the previous quarter
X4 Pharmaceuticals's net income has plunged by 123% from the previous quarter but it has soared by 63% YoY
XFOR's operating income has soared by 66% year-on-year but it is down by 41% since the previous quarter
Growth
What is X4 Pharmaceuticals's growth rate over time
Valuation
What is X4 Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.76
P/S
17.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.24
The EPS has dropped by 138% since the previous quarter but it has soared by 67% year-on-year
The stock's price to book (P/B) is 97% less than its last 4 quarters average of 58.5 and 88% less than its 5-year quarterly average of 13.7
The equity has plunged by 63% from the previous quarter and by 57% YoY
The revenue has surged by 128% since the previous quarter
Efficiency
How efficient is X4 Pharmaceuticals business performance
The company's return on equity has shrunk by 160% QoQ but it has surged by 50% YoY
XFOR's return on assets has dropped by 124% since the previous quarter but it has surged by 65% year-on-year
XFOR's return on invested capital has surged by 85% year-on-year
The ROS has declined by 50% since the previous quarter
Dividends
What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XFOR.
Financial health
How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 18% greater than its total liabilities
The quick ratio has declined by 37% year-on-year and by 32% since the previous quarter
The company's current ratio fell by 36% YoY and by 30% QoQ
X4 Pharmaceuticals's debt to equity has soared by 169% from the previous quarter
The equity has plunged by 63% from the previous quarter and by 57% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.